Life Science Companies in Europe

Eurofins Genomics is a leading international provider of genomic services, specializing in next-generation sequencing, genotyping, and gene expression analysis. Based in Ebersberg, Germany, we support a diverse range of sectors including pharmaceuticals, diagnostics, agriculture, and research. As part of the Eurofins Scientific Group, a global life science leader with a presence in 61 countries, we leverage our extensive expertise and cutting-edge technology to deliver tailored genomic solutions. Our commitment to quality and precision, combined with our ISO 17025 accreditation, ensures reliable and impactful results for our clients worldwide. We offer a comprehensive portfolio of products and services, from custom oligonucleotide synthesis and gene synthesis to advanced sequencing and bioinformatics analysis, empowering scientific discovery and innovation.

TEK Optima Research is a leading provider of advanced imaging systems and AI-powered software solutions, based in Wimborne, Dorset, UK.

We specialize in designing and manufacturing high-performance hardware and innovative DeepInsight cell fingerprinting technology for the Biotech, Medical, and related microscopic imaging industries. Our solutions enable faster, more accurate results for researchers and clinicians.

TEK Optima Research combines cutting-edge hardware development with sophisticated data analytics and AI to deliver a complete imaging platform. We support a wide range of applications, from drug discovery to clinical diagnostics.

Founded in 2019, we’ve quickly established ourselves as a trusted partner for organizations seeking to push the boundaries of microscopic imaging. We currently employ a team of 5 dedicated professionals, operating from our R&D office and manufacturing facility in Dorset and a secondary R&D office in Durham, NC.

Genomics is a pioneering transatlantic TechBio company based in Oxford, UK, specializing in **genomic prevention** and transforming healthcare through the power of genomics.

We leverage large-scale genetic information to provide accurate, personalized risk estimates for common diseases and cancers, enabling early interventions and tailored screening. Our proprietary algorithms and databases link minute variations across the entire genome to biological measurements and disease outcomes, generating population-level insights for healthcare systems and individual-level risk assessments for clinicians.

Genomics partners with leading life sciences and biotech companies, including Novo Nordisk and Vertex, offering a unique approach to sustainable healthcare. Our team of over 150 experts – including world-leading genomic scientists, computational biologists, and data scientists – is dedicated to bringing subject-leading science to a global audience, ultimately transforming lives.

Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. Two of Antabio’s programs have received Wellcome Trust Seeding Drug Discovery Awards to date: [i] a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections and [ii] a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the long-term management of chronic respiratory infections. The company’s lead product is expected to enter the clinic in 2019 with a fast track to anticipated marketing approval. Antabio has built a best in class, international team of experts in the field and is currently seeking to raise additional funds to progress its pipeline up to the next value inflection point. Our company is also looking to in-license additional assets focused on Gram-negative antibiotic resistant therapies. Please visit www.antabio.com and follow us on Twitter @antabio

We are a precision medicine pioneer in psychiatry based in Munich. Founded in 2010, our privately held biotech company combines the development of machine learning-enabled companion diagnostics with specific therapeutics to personalize the treatment of neuropsychiatric disorders with a focus on depression. Our ultimate goal is to improve the lives of patients by developing highly disruptive solutions for their high unmet medical needs. We strives to reduce not only the immense individual burden, but also the societal impact of these diseases. We develop patented genetic tests and combines those with innovative exclusively in-licensed medications, resulting in precise therapies for depression and other neuropsychiatric disorders.

BDD Pharma combines drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and create new value-added products. Rapid parallel clinical testing with BDD SWIFT significantly reduces the time from product concept to clinical success. Recognizing that one size does not fit all we specialise in providing responsive, flexible and innovative solutions to our customers. Our patented delayed release technology OralogiK provides unrivalled control of drug release at the right place and time. Our clinical division provides a full clinical package, including protocol development, study documentation design and regulatory authority submission, through to close out and production of ICH GCP-compliant clinical study report. We specialise in gamma scintigraphy, a powerful and versatile technology used to investigate the in vivo behaviour of your formulation. Coupled with pharmacokinetic data, this technique can be used to provide information on time /site of disintegration, gastric emptying, GI transit and intra/ inter individual differences.

At abcam, we believe the scientific community goes further, faster when we go there together. And to keep on making ground-breaking discoveries, we need to work together in new ways. That’s why we’re constantly innovating to help scientists drive their research forward by providing products and solutions that play an essential role in fundamental research, drug discovery, diagnostic and therapeutic applications. We started with a simple mission: to provide the best biological reagents to life scientists worldwide. Today, we help 750,000 researchers in over 130 countries deliver faster breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders.

Automata was founded with a clear aim: to unlock human potential with automation. Through our collaboration with some of the world’s leading pathology labs, we’ve developed the most comprehensive lab automation platform on the market. By simplifying environments and empowering people, Automata enables labs to scale with precision and creates new opportunities for scientists to accelerate innovation.

Biorelate helps scientists solving the most difficult biomedical challenges of today. We do this by curating truths from existing knowledge, enabling smarter and faster research & development.

Abionic, an in vitro diagnostics (IVD) company, was founded in 2010 as a spin-off from the Swiss Federal Institute of Technology of Lausanne (EPFL). Abionic is aiming to make a difference in patient care through the cutting-edge nanofluidic technology based ultra-rapid diagnostic platform, helping healthcare professionals to make clinical decisions at the point of care.

Aiforia equips pathologists and scientists in preclinical and clinical labs with powerful deep learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud based Aiforia products and services aim to escalate the efficiency and precision of medical image analysis, across a variety of fields from oncology to neuroscience and more. From empowering researchers in the identification of novel biomarkers of disease, and supporting R&D scientists in speeding up time-to-market of novel drugs, to helping pathologists enhance the accuracy of cancer diagnostics — Aiforia has the expertise and experience to transform healthcare all the way from discovery to diagnosis.

AMADIX is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is extending people's lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear.

APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies. Our company has a well balanced portfolio with one product on the market and several promising products from clinical to pre-clinical stages. As for the product on the market, APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients. We out-licensed Qarziba® globally to EUSA Pharma Ltd, for which it holds exclusive rights to this product. APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. Our development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.

Who we are: atai is a biopharmaceutical company that leverages a decentralised platform approach to incubate and accelerate the development of highly effective mental health treatments that address the unmet needs of patients. Our vision: To heal mental health disorders so that everyone, everywhere can live a more fulfilled life. Our approach: By pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based treatments.

b.fab is specialized in the efficient conversion of CO2 and hydrogen (H2) from renewable energy into biotechnological value chains. CO2 and water are abundantly available and therefore it is our starting point to build a sustainable bioeconomy. We use formate as our central mediator to bind and store CO2 and H2 (made from water) in liquid form. Our bioprocesses start with the feedstock formate and we use Synthetic Biology to design specific pathways and to convert formate into value-added chemicals. Our platform is build on anaerobic and aerobic microbial production hosts to provide flexibility in the process design and adaptation to specific product requirements. We apply laboratory automation, high-throughput experimentation and advanced bioprocess development in an agile environment to develop new bioprocesses efficiently and in a minimal time frame. b.fab is dedicated to establish a Formate Bioeconomy in the coming years, and thus, providing an economical and sustainable new way to produce value-added chemicals for various industries.

BC Platforms is a global leader in building data networks for the life sciences industry and provides versatile technology platforms for personalised medicine, accelerating the translation of innovations into clinical practice. We convert complex biological information collected in the healthcare setting into actionable insights. With our innovative technology we are creating a patient centric infinity loop between the life sciences and healthcare sectors. Data we generate, harmonise, and manage, from diverse biobanks and healthcare institutions, is made accessible for pharmaceutical and biotech companies to enhance their core strengths in research and development. In parallel, we enable stratification of patients towards targeted therapies, delivering on the promise of more personalized healthcare. Our high performing genomic data discovery and analytics platform enables flexible data integration, secure analysis, and interpretation of molecular and clinical information. We have developed a Global Data Partner Network, BCRQUEST.com, which allows access to high-quality real-world data. This rapidly growing network has a footprint across many sites, including networks of major hospitals, covering 20 countries in five continents, providing standard of care data for over 23 million patients. Our platforms seamlessly facilitate access to highly enriched data for pharmaceutical research and development. Founded in 1997 from a MIT Whitehead project spinoff, we have a strong scientific heritage underpinned by over 25 years of working in close collaboration with a network of leading researchers, developers, and industry partners. We have global operations with our headquarters in Zurich, Switzerland, R&D in Espoo, Finland, and Singapore, as well as a presence in London and Boston. For more information, please visit www.bcplatforms.com.

Our ambition is to play a key role in tackling climate change, by enabling green chemistry for every industry. We do this by creating the most general and efficient technology platform for chemical production that the world has ever seen. That’s a big claim, but we can stand behind it. By bio-upgrading the chemical industry with our cell-free biomanufacturing platform, we can produce the products that modern society relies on in a truly sustainable way. The technology platform utilises nature’s catalysts, enzymes, by combining the power of biology with the efficiency of the chemical industry in a best-of-both-worlds solution. EnginZyme is recognised as a Technology Pioneer by World Economic Forum and backed by Sofinnova Partners, Industrifonden, SEB Greentech VC, Bunge Ventures, Almi Invest GreenTech Fund, and Navigare Ventures.

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry. C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3(R)) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. C4X Discovery is advancing its in-house pipeline that is primarily focused on the high value therapeutic areas of inflammation, neurodegeneration and cancer (including immuno-oncology) with a number of new drug candidates identified and further progress made towards the pre-clinical licensing discussions. In selecting new targets and executing new drug discovery programmes, C4X Discovery focuses on high-value disease areas that are the subject of significant licensing activity and will continue to also maximise value from opportunistic areas such as addiction and diabetes. The Company recently signed a licensing agreement with Indivior for a pre-clinical addiction programme worth up to $294m. The Company was founded as a spin-out from the University of Manchester. t has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD to reach multiple value inflexion points since IPO. Website: www.c4xdiscovery.com Twitter: @C4XDiscovery

Building the next generation of cloud computing, DeepSquare democratises access to performant yet affordable High Performance Computing by delivering a platform that seamlessly interconnects users with a grid of distributed supercomputing resources. Your AI Powerhouse!

Elsa Science strives to contribute to a future where chronic disease is minimized. Where people who are diagnosed can reach optimal health sooner and live a new life faster, and to its full potential. Elsa Science was established in 2017 by a team of influential scientists and award winning designers who have a passion to improve the health of people living with chronic disease. Driven by science, self-reported patient data, and individualized care, and through meaningful content and design, Elsa Science aims to make science accessible and put it in the hands of the people living with a chronic disease. Providing motivation and education through two tools - the Elsa Science Self-care app and Clinical Dashboard, bring patients and families closer together with healthcare providers through seamless data sharing. Our digital solution provides a powerful communication tool for a greater good, to better manage the illness, improve healthcare, and empower the individual to proactively self-care.

Fluidic Analytics designs, develops and manufactures tools that seek to revolutionise the way proteins are characterised, allowing our customers to understand the machinery of life. We envision a world where information about proteins and their behaviour transforms our understanding of how the biological world operates, and helps all of us make better decisions about how we diagnose diseases, develop treatments and maintain our personal well-being. By building the world’s best tools, software and services for protein characterisation and making them universally accessible in the lab, in the clinic or at home, we are making this vision a reality not just for a small group of expert users, but for everyone who can benefit. Twitter: @fluidicanalytic

Labster is a fast-moving, award-winning company that focuses on revolutionizing the way science is taught to students all over the world. Virtual labs are simulated learning environments that allow students to complete laboratory experiments online and explore abstract concepts and difficult theories without stepping into a physical science lab. Our labs are based on mathematical algorithms supporting open-ended investigations and are combined with gamification elements such as an immersive 3D universe, storytelling and a scoring system that stimulates students' natural curiosity and highlights the connection between science and real-world issues. Our customers include global leading institutions such as Harvard, MIT, Stanford, Exeter University and ETH Zurich. Article published by Mads Tvillinggaard Bonde, in Nature Biotechnology (July 2014) supports that using traditional teaching (incl. wet-labs) in combination with virtual labs potentially increases learning outcomes by 101%.

Materials technology startup unlocking the potential of nanofibers with #halospinning for cultured meat, tissue engineering, wound care, filtration, and more. Our proprietary high-throughput nanofiber production technology HaloSpin™ is the fastest solution-spinning technology. We are especially focused on the production of bio-based nanofibers, but can work with variety of different polymers. Compared to electrospinning, our technology enables over 90% price reduction and is the ideal solution for applications such as tissue engineering, cultured meat, drug discovery, wound care, energy storage, filtration, and more. We are providing nanofiber manufacturing as well as development services for companies to develop the materials for a specific application. We have developed our own edible 100% vegan scaffolds for cultured meat and are continuously developing new products also on our own.

GFBiochemicals is a biochemical company that specializes in the research, development, production and business development of bio-based and renewable chemicals. We provide high-quality, bio-based chemicals to businesses across the world. Our focus is green chemistry – a sustainable alternative to traditional oil-based chemistry. Our technology is proprietary and has been developed in-house over many years. GFBiochemicals is headquartered in Paris, France and has subsidiaries in Geleen, the Netherlands and Minneapolis, USA. GFBiochemicals acquired Segetis, in 2016, as part of our growth strategy to integrate further in the downstream value chain of levulinic acid. After years of research and development, we started production of levulinate based biosolvents in 2018, by our Joint Venture Company, NXTLEVVEL Biochem (www.nxtlevvel.com). We have an experienced team of researchers, chemical engineers, and business developers.

Gradientech is a Swedish biotech and diagnostics company dedicated to support the modern microbiology lab with state-of-the-art solutions to facilitate the workflow with time-critical samples. Our product QuickMIC® is an ultra-rapid system for antibiotic susceptibility testing (AST) of positive blood culture samples from sepsis patients. QuickMIC® is a scalable system with each instrument module analysing one sample against multiple antibiotics, well-suited for small and larger clinical laboratories. MIC values are reported in as short as 2 hours, making it more rapid than any other diagnostic system for phenotypic AST on the market. Gradientech’s technology combines microfluidics with live cell imaging to study cell responses in a linear concentration gradient. Our technology is a perfect match for many biological applications. Gradientech holds an ISO13485 certification.

Imagen Therapeutics is a biotech company based in the UK, with an ongoing commitment to improving the outcomes of cancer patients by accelerating drug discovery and the development of new cancer therapies. Our main activities include offering personalised clinical diagnostic services to cancer patients, offering contract research services, and developing a world-leading well-characterised Biobank.

Leyden Labs aims to help people live their lives to the fullest. Our platform targets commonalities of viral families to protect humanity from known and future viruses. Our portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many variants of respiratory viruses, including ones in the influenza and coronavirus families. The Leyden Labs’ energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

At LAVA, we are focused on applying our expertise in gamma-delta T-cell engagers (TCEs) to transform cancer therapy. We refer to our compounds as gamma-delta bispecific T-cell engagers, or gamma-delta bsTCEs. Our platform generates therapeutics that specifically activate a unique and relatively abundant effector gamma-delta T-cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T-cells that have the ability to trigger activity of immune cells of both the innate and adaptive immune system. Our gamma-delta bsTCEs have demonstrated superior efficacy and safety profiles compared to other bsTCE approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy tissue. To date, we are the only company developing bispecific gamma-delta T-cell engaging antibodies for the treatment of cancer. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor specific antigen CD1d, which can be overexpressed in multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML), among other tumor types. LAVA-051 will enter a Phase I/IIa study in 1Q21.

LUMICKS is the leading supplier of dynamic single-molecule and cell avidity analysis instruments. Our instruments enable – for the first time – the analysis of complex dynamic details related to the behavior and interaction of single molecules and cells. Built upon innovative and Nobel Prize-winning technologies, such as optical tweezers (Nobel Prize for Physics 2018), and STED super-resolution (Nobel Prize for Chemistry 2014), our tools enable the understanding of life to the smallest detail. Our goal is to advance science and improve human health, by providing tools that unlock the measurement of forces and interactions in biology. For the first time ever, our unapparelled solutions can assist research by directly linking structural and ‘omics analysis to functional outcomes at both a molecular and a cellular level. This is achieved by applying and measuring forces around biological interactions, enabling the detailed real-time analysis of underlying biological mechanisms.

Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies.

Methinks vision is to provide universal and timely diagnosis for life-saving treatments worldwide. Our first focus is on stroke, the second cause of death and a major cause of disability in the world. Our product is an artificial intelligence medical imaging software capable of performing stroke triage and unlock stroke treatments potential from non-contrast CTs. Methinks is a VC backed digital health start-up that recently won the prestigious EIC Accelerator of the European Commission and has obtained two gold medals in the RSNA Kaggle competitions. The recent funding of the company will allow us to grow rapidly and we are looking for exceptional and passionate individuals to help us face these challenges and build together a unique company.

Metrion Biosciences is a UK-based Contract Research Organization specialising in high quality ion channel screening and drug development expertise. We aim to provide our customers with access to a range of in vitro screening services that includes cardiac safety (hERG, CiPA panel of human cardiac ion channels) and neurotoxicology testing and phenotypic assays on a fee-for-service or collaboration basis. We pride ourselves on being able to provide a flexible and cost effective service with an unparalleled level of expertise. Collectively, our management team have amassed over 80 years of experience in ion channel drug discovery and our clients can access this high level of expertise as part of our dedicated service.

Mission Therapeutics is a private, drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need. Mission has built a world-leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’. Mission’s DUB platform is yielding a rich pipeline of novel therapeutics for the benefit of patients across therapeutic areas. Mission’s strategy is to create value by advancing its pipeline programmes through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Mission’s leadership team has a wealth of international, commercial and scientific experience, and the company has strong links with key academic and research centers including Cancer Research UK Laboratories and the Jackson Laboratories at the Gurdon Institute, University of Cambridge. The Company has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. Mission is based at the Babraham Research Campus, south of Cambridge.

Netabolics, part of Microsoft for Startups Founders Hub, develops an insilico target selection platform that integrates the predictive power of artificial intelligence and machine learning (AI/ML) with the explainable nature of biosimulation based on first principles of physics and biology.

Nuclera is making biology accessible by providing researchers a desktop bioprinter capable to produce genes and proteins in one day. Biological research and drug discovery projects begin with and rely on proteins. However, using traditional methods to obtain proteins of interest can take up to 6 months and often include many trials and failures. What if there was an easier way? At Nuclera, our mission is to better human health by making proteins accessible. We believe that providing rapid access to high-quality, soluble, active proteins at the benchtop will allow researchers to accelerate their protein projects. Fail fast, succeed faster. Our eProtein Discovery™ system automates construct screening for the best soluble expression and purification yields of different proteins in under 24 hours. From there, protein scale-up happens the next day (up to the mg scale) right on the benchtop - delivering reliable protein in-hand in less than 48 hours. Nuclera’s technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing rapid progress on protein projects through a benchtop, automated, high-throughput protein access system. Founded in 2013 by PhD students at the University of Cambridge, the company now has a presence in Cambridge, UK and Boston, MA employing over 100 employees.

See protein, DNA and RNA molecules that make life work, in nanoparticles, viruses, bacteria, cells and tissue. We believe that understanding science at a molecular level will fundamentally allow you to unlock new discoveries, so we created our flagship product, The Nanoimager. We built the world's first desktop compatible compact super-resolution microscope, but we did it our way. Our teams have a restless enthusiasm to bring technologies like super-resolution to a new community of researchers and we continue working until barriers of accessibility and affordability are addressed. Our mission is to ensure research and collaboration tools are available to those willing to ask why or how things are the way they are and answer questions never asked before. We can’t wait to see and hear about what new questions you will ask!

Our mission is to help life sciences companies accelerate drug development for improved patient outcomes, and we do this by championing the power of data. Our main product DISQOVER is an optimized search or knowledge platform which draws on semantic technology and an ontology-based knowledge graph to find links between data across databases (internal data, public data and third party data) faster and more efficiently. The platform has been developed for the pharmaceutical and biotech industries. There are thousands of health research databases, clinical trials, literature reviews, patient studies, etc. available. Before setting up a new study, scientists first need to check what kind of research has already been done – both internally and externally – on, for instance, growth hormone applications for a particular disease. In many companies, even internal information resides in hundreds of different databases, each with their own interface and search logic. As a consequence, just finding this kind of background information is a very time-consuming process. This is where DISQOVER comes in. One of the assets is that we use semantic technology to find logical but often hidden connections between internal and external data, allowing you to easily combine information from a multitude of different sources. As such, pharma and biotech companies can save valuable time and money that they can now invest in developing new medicines or treatments. Customers include: AstraZeneca, AmGen, Medidata, Prinses Máxima Institute, Aelin Therapeutics and more. DISQOVER is used amongst others by scientific researchers, bioinformaticians, and data scientists. Try DISQOVER: our community edition is always up-to-date and accessible via www.ontoforce.com (choose “try now” top right corner)

We bring automated cell-monitoring solutions for cell & gene therapy, vaccine industry and life sciences applications. Our microscopes are easy-to-use, label-free and non-invasive tools for the three-dimensional, real-time imaging of living cells. Based on patented differential digital holography technology, our advanced systems generate reliable, high-quality holographic images providing highly-reproducible tracking of: - cell density - morphology - cell viability - viral infection kinetics - cell activation status Direct Benefits Our technology can benefit a range of applications, from R&D to manufacturing processes, and enable significant cost reduction and quality improvement. Our microscopes are particularly convenient and robust for automated cell culture monitoring, analysis and quality control.

Our mission is to improve patient lives and the sustainability of the global healthcare ecosystem by broadening the availability and accessibility of biosimilars.

AXELEROS Preclinical Development is a Brussels-based preclinical development consultancy specializing in regulatory affairs and preclinical study management for the biopharmaceutical industry.

We support clients – including biotech companies, SMEs, and research institutions – throughout the entire preclinical process, from initial strategic planning to regulatory submission. Our team provides expert guidance on navigating the complex landscape of global regulations, ensuring your innovations meet the highest standards and accelerate their journey to market.

Our core services encompass a comprehensive suite of offerings, including strategic regulatory planning, global regulatory submissions, sourcing and management of toxicology and pharmacology studies, and toxicological risk assessments. We are dedicated to helping you bring your groundbreaking therapies to patients worldwide. We also offer European Public Affairs support to unlock valuable funding opportunities for your healthcare projects.

EpiXlife is a biotechnology company based in Valencia, Spain, specializing in innovative wellness solutions for healthcare professionals.

We empower professionals across Argentina, Brazil, Colombia, Mexico, Spain, and Uruguay with cutting-edge technologies and personalized training.

EpiXlife distinguishes itself through its integrated approach, combining advanced bioprobes, comprehensive training programs, and targeted marketing strategies, all supported by ongoing expert support. We are dedicated to transforming the wellness industry and helping professionals maximize their impact on patient lives.

Our mission is to provide professionals with the tools and knowledge they need to thrive in a rapidly evolving landscape, fostering a future where wellness is accessible and effective for all.

CNRS UMR8199 is a French research institute based in Lille, specializing in the study of metabolic diseases and their genetic causes.

Our team, led by Pr. Philippe Froguel, focuses on understanding the molecular mechanisms behind diseases like diabetes and obesity, with the ultimate goal of developing more effective prevention and treatment strategies.

We conduct cutting-edge research in genomics and molecular physiology, contributing to a deeper understanding of these complex conditions and paving the way for personalized medicine. We are a key player in the **biotechnology research** sector, collaborating with leading institutions globally.

Established in 1995, CNRS UMR8199 has grown to a team of 11 researchers, furthering our commitment to advancing scientific knowledge and improving patient outcomes.

Orano Med is a French research and development company specializing in the production of high-purity lead-212 (Pb-212), a rare radioactive isotope, and driving innovation in targeted cancer therapies.

Based on a program initiated in 2005, Orano Med has pioneered the targeted alpha therapy (TAT) approach, recognizing and destroying cancer cells while minimizing harm to healthy tissue.

Leveraging Macrocyclics, Inc., a key component of Orano Med, the company operates a robust industrial platform for Pb-212 production and maintains a strong pipeline of research and development, including 18 clinical trials and over 30 patents.

With 220 employees across France and the United States, Orano Med is committed to advancing the field of nuclear medicine and improving patient outcomes through cutting-edge radiotherapeutic solutions.

Iktos is a Paris, France-based artificial intelligence company revolutionizing drug discovery.

We specialize in applying generative AI to medicinal chemistry, enabling pharmaceutical companies and research institutions to design and optimize molecules in silico. Our proprietary SaaS platforms, Makya™ and Spaya™, combined with our AI-driven robotics platform, dramatically accelerate the entire drug development process – from initial design to synthesis and testing.

Iktos is at the forefront of innovation, leveraging cutting-edge technology to reduce R&D timelines and increase the success rate of new drug candidates, particularly in oncology and autoimmune diseases. We are proud to have received significant investment and recognition, including a recent EIC Accelerator grant, demonstrating our commitment to transforming the future of drug discovery.

Harnessing the power of deep learning on 3D molecular configurations to deliver medicines of transformational efficacy to patients.

Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.

Hedia’s vision is to improve quality of life for people with diabetes and make the best diabetes management tools available to as many as possible. Hedia Diabetes Assistant (HDA) is a class IIb medical device, aiming to help improve management of insulin-requiring diabetes and thereby lead to desired health outcomes such as stability of blood glucose levels. Based on habits of the individual person with diabetes and personalised input, HDA generates insulin recommendations helping the person with diabetes in their insulin treatment. In addition to our diabetes management tool we offer an education universe for healthcare professionals. The platform has been developed in close collaboration with patients, nurses, and other key stakeholders to ensure the best fit for the needs of living with diabetes.

Atrandi Biosciences is breaking new ground in high-throughput analysis technologies. Providing simple-to-adopt and easy-to-use droplet microfluidics and high-throughput screening (HTS) workflows. Droplet microfluidics technology is at the core of our products and provides an unmatched platform for exploring the complexity of biology in a high-throughput manner. Droplet microfluidics enables compartmentalizing molecular biology reactions into millions of pico-liter droplets, empowering you to study biological samples at the resolution of single cells and single molecules. Our work is at the intersection of life sciences, engineering, and machine learning. We deliver elegant solutions and novel tools for groundbreaking high-throughput research by integrating different technologies.

Proteins are the most advanced nanotechnology we know of. At Adaptyv Bio we’re building a next-gen protein foundry to allow you to synthesize and test any protein you design.